Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.
Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) is indicated for symptomatic treatment of focal spasticity of:
- Upper limbs in adults
- Lower limbs in adults affecting the ankle joint
Please click here to see the full therapeutic indications.
CLIMB Online
Adult Spasticity
Dysport® Injection Handbook
A reference guide to the administration of Dysport for the treatment of adult focal spasticity, including the identification of muscles using ultrasound, and the recommended injection technique per muscle.
DYS-UK-008782
Dysport® Dose Map for Adult Focal Spasticity
A reference guide to the dosing of Dysport® for the treatment of adult focal spasticity
DYS-UK-008777
Management of Spasticity in Adults – eLearning Module
20 minutes
An overview of the management of adult spasticity with a focus on the principles of spasticity and upper motor neurone syndrome pathophysiology, the effects of adult spasticity, and management and treatment options
DYS-UK-008754
Diagnosis and assessment of spasticity in adults – eLearning Module
20 minutes
An introduction to spasticity diagnosis and assessment with a focus on functional anatomy and impairment in spasticity, range of motion and mobility
DYS-UK-008756
Management of spasticity with BoNT-A – eLearning Module
20 minutes
An introduction to botulinum toxin with an overview of the mechanism of action of botulinum toxin type A, patient selection and Dysport® for the treatment of adult spasticity
DYS-UK-008757